BIOMARKER:

KIF5B-RET fusion

Entrez ID:

Related biomarkers:

‹

›

KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	RXDX-105 Sensitive: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	lenvatinib Sensitive: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	sunitinib Sensitive: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	vandetanib Sensitive: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	nintedanib Sensitive: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	cabozantinib capsule Sensitive: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Lung Cancer Lung Cancer	alectinib Resistant: C3 – Early Trials
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	nivolumab Sensitive: C4 – Case Studies
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	pembrolizumab Resistant: C4 – Case Studies
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Resistant: C4 – Case Studies
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	everolimus + vandetanib Sensitive: C4 – Case Studies
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	cabozantinib tablet Resistant: C4 – Case Studies
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	cabozantinib tablet Sensitive: D – Preclinical
KIF5B-RET fusion KIF5B-RET fusion	Lung Adenocarcinoma LUAD	vandetanib Sensitive: D – Preclinical
KIF5B-RET fusion KIF5B-RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: D – Preclinical